***Background.*** Group B Streptococcus (GBS) is a primary cause of infant sepsis and meningitis. As maternal anti-capsular (GBS) antibody is protective, maternal immunization could protect newborns. Here, the safety and immunogenicity of various doses, schedules and adjuvants of a trivalent GBS glycoconjugate vaccine (Novartis) were evaluated in non-pregnant women (clinicaltrials.gov NCT01150123).

***Methods.*** In a phase Ib, single-centre, randomized, observer-blind, placebo-controlled study, 678 healthy 18--40 year-old non-pregnant women were enrolled in two cohorts. Each cohort was randomized to 9 groups, to receive either placebo, or 1 or 2 doses (day 1 and 31) of one of 4 formulations of trivalent GBS vaccine: 5 or 20 µg of each glycoconjugate for serotypes Ia, Ib and III, with or without AlOH~3~ (cohort I); or with half or full doses of MF59® (cohort II). Solicited local and systemic reactions and adverse events were assessed. Antibodies were measured by ELISA at days 1, 61 and 361.

***Results.*** Relatively low antibody levels (all serotypes) were found at baseline, similar in all groups, and remained unchanged throughout the study after placebo. Vaccination significantly increased antibody levels. In cohort I groups Geometric Mean Ratios (Day 61:Day 1) were 19--45, 23--47 and 15--36 for serotypes Ia, Ib and III, respectively; 70--93%, 50--74%, and 46--73% of groups achieving levels ≥ 1 µg/mL. There were no clear differences between 5 and 20 µg doses (except for a trend to higher responses with 20 µg vs 5 µg in women with no detectable antibodies at baseline), 1 or 2 injections, or use of AlOH~3~. In cohort II, no added benefit of MF59® adjuvant was observed. Across all subjects, antibodies waned by Day 361, but remained significantly higher than placebo.

No vaccine-related serious adverse events were reported; adverse events were mostly mild to moderate. Local reaction rates were higher with vaccine than placebo, and increased with AlOH~3~ and MF59®. Systemic reaction rates were comparable across all groups.

***Conclusion.*** GBS vaccine was immunogenic and well-tolerated in non-pregnant women. No clear added benefit was observed from higher dosage, two injections or adjuvants, but a trend towards higher responses was observed with 20 µg vs 5 µg in women with undetectable baseline antibody.
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